_part-1-dna-damage-response-and-parp-inhibition.jpg "Part 1 -DNA Damage Response and PARP inhibition from parp Video Screenshot Preview")
GalleryPlay Video:
(Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
⏲ Duration: 1 min 85 sec
✓ Published: 09-Jul-2019
✓ Published: 09-Jul-2019
Description:
Short chapter from the Mechanism of Action of PARP inhibitors and Targeting DNA Damage Response (DDR) video
Short chapter from the Mechanism of Action of PARP inhibitors and Targeting DNA Damage Response (DDR) video
Share with your friends:
Whatsapp | Viber | Telegram | Line | SMS
Email | Twitter | Reddit | Tumblr | Pinterest
Related Videos
_more-ovarian-cancer-patients-benefit-from-maintenance-combined-targeted-therapy.webp "Prof Isabella Ray-Coquard speaks to ecancer at ESMO 2019 in Barcelona about the PAOLA-1/ENGOT-ov25 Phase III trial, which showed the benefits of treating advanced ovarian cancer patients with bevacizumab and PARP inhibitor olaparib in the first-line setting. nnShe explains that this intensive regimen was given to patients both with and without a BRCA mutation. While both groups were found to have extended progression-free survival, this was more pronounced in the subgroup of patients with BRCA m")
⏲ 2 min 65 sec ✓ 28-Sep-2019
_niacin-is-neuroprotective-in-a-fly-model-of-parkinsons-disease.webp "https://doi.org/10.1242/bio.022186nnLehmann et al.")
_parp-inhibitor-olaparib-as-treatment-for-pancreatic-cancer-patients-with-brca-gene-mutations.webp "Dr Hedy Kindler talks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about results from the POLO trial looking at the use of the PARP inhibitor olaparib as treatment for pancreatic cancer patients with BRCA gene mutationsnnShe explains that this trial is the first phase III trial showing that a targeted treatment in a biomarker selective group of pancreatic cancer patients can improve progression free survival.nnDr Kindler reports that patients who received ol")
⏲ 1 min 78 sec ✓ 02-Jun-2019
_immunomodulatory-effects-of-parp-inhibition-in-brca1-deficient-triple-negative-breast-cancer.webp "Dr Constantia Pantelidou speaks to ecancer at the 2019 American Association for Cancer Research (AACR) meeting about a study which looked at the immunomodulatory effects of PARP inhibition in BRCA1-deficient triple-negative breast cancer (TNBC).nnShe reports that PARP inhibitors induce an anti-tumour immune response in BRCA1-deficient TNBC but not in BRCA1-proficient TNBC.nnDr Pantelidou explains that this T cell recruitment is mediated through activation of the STING pathway and this activation")
⏲ 1 min 67 sec ✓ 09-Apr-2019
_asco-2022-latest-in-prostate-cancer-including-parp-inhibitors.webp "Dr Neal Shore (Carolina Urologic Research Center, Myrtle Beach, USA), Prof Phil Cornford (Royal Liverpool University Hospital, Liverpool, UK), Prof Eleni Efstathiou (Houston Methodist Cancer Center, Houston, USA) and Prof Cora Sternberg (Weill Cornell Medicine, New York, USA) discuss the latest in prostate cancer, including PARP inhibitors. nnInitially, they discuss the latest trials and updates in prostate cancer including PROPEL, MAGNITUDE and the ARCHES trial.nnThey discuss the use of Lutetiu")
_parp11.webp "PARP11 from parp")
_which-different-parp-inhibitors-are-available.webp "This series of animations investigates the current role of PARP inhibitor use in prostate cancer, and what we might expect in the future and has been developed by Prof Phillip Cornford in association with ecancer.nnPARP inhibitors treat certain types of cancer by blocking the PARP enzymes in cells. These enzymes help repair DNA damage, so blocking them can prevent cancer cells from repairing.nnPARP inhibitors have so far demonstrated efficacy in ovarian, breast, pancreatic, peritoneal and metast")
_parp-inhibitor-olaparib-slows-progression-of-advanced-prostate-cancer.webp "Prof Maha Hussain presents data from thePROfound trial during a press conference at the 2019 ESMO congress.nnThis was a trial evaluating the PARP inhibitor olaparib vs new hormonal agents in patients with metastatic, pre-treated prostate cancer whose cancer cells had faulty DNA repair genes.nnSign up to ecancer for free to receive tailored email alerts for more videos like this.necancer.org/account/register.php")
_more-ovarian-cancer-patients-benefit-from-maintenance-combined-targeted-therapy.jpg)
_niacin-is-neuroprotective-in-a-fly-model-of-parkinsons-disease.jpg)
_parp-inhibitor-olaparib-as-treatment-for-pancreatic-cancer-patients-with-brca-gene-mutations.jpg)
_immunomodulatory-effects-of-parp-inhibition-in-brca1-deficient-triple-negative-breast-cancer.jpg)
_asco-2022-latest-in-prostate-cancer-including-parp-inhibitors.jpg)
_parp11.jpg)
_which-different-parp-inhibitors-are-available.jpg)
_parp-inhibitor-olaparib-slows-progression-of-advanced-prostate-cancer.jpg)
![[+]](/images/menu.gif){kind=small}